New combo attack on aggressive breast cancer shows promise in early trial
NCT ID NCT06682195
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for women with triple-negative breast cancer. About 35 participants will receive the combination, then undergo surgery. The main goal is to see how many have no cancer cells left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with chemotherapy drugs epirubicin, cyclophosphamide, and albumin-bound paclitaxel
What this could lead to
If successful, this could lead to a more effective treatment approach for triple-negative breast cancer before surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 35 participants and no comparison group. The combination may cause side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, China
Contact
-
Jinhua Municipal Central Hospital
RECRUITINGJinhua, China
Contact
-
Nanchang People's Hospital
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact
-
Nantong First People's Hospital
RECRUITINGNantong, China
Contact
-
Shanxi Provincial Cancer Hospital
NOT_YET_RECRUITINGShanxi, China
Contact
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact
-
The First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, China
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi'an, China
Contact
-
Xinjiang Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITINGXinjiang, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, China
Contact
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
Contact